NCT00060307View on ClinicalTrials.gov

Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

May 31, 2007

Conditions
Recurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00060307 - Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | Biotech Hunter | Biotech Hunter